Triple

T1143499
Position Surface form Disambiguated ID Type / Status
Subject Committee for Advanced Therapies E23508 entity
Predicate website P69 FINISHED
Object https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat E23508 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat | Statement: [Committee for Advanced Therapies, website, https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat
Context triple: [Committee for Advanced Therapies, website, https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat]
  • A. Committee for Advanced Therapies chosen
    The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • B. Committee for Medicinal Products for Veterinary Use
    The Committee for Medicinal Products for Veterinary Use is the European Medicines Agency’s scientific committee responsible for evaluating and providing opinions on veterinary medicines in the European Union.
  • C. Committee for Orphan Medicinal Products
    The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • D. European Medicines Agency
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • E. Committee for Herbal Medicinal Products
    The Committee for Herbal Medicinal Products is a scientific body within the European Medicines Agency that evaluates and provides guidance on the safety and efficacy of herbal medicines in the European Union.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a493ef399c8190b04b9146d2314f59 completed March 1, 2026, 7:30 p.m.
NER Named-entity recognition batch_69a4bc4e93d48190b9fea886bf61aad7 completed March 1, 2026, 10:23 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac59b2395c81909d4608bdaf1d57e8 completed March 7, 2026, 5 p.m.
Created at: March 1, 2026, 7:44 p.m.